Icotinib

Drug Profile

Icotinib

Alternative Names: BPI-2009; BPI-2009H; Conmana; Icotinib hydrochloride

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Beta Pharma
  • Developer Beta Pharma; Zhejiang Betta Pharma
  • Class 3-ring heterocyclic compounds; Alkynes; Antineoplastics; Crown ethers; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Brain metastases; Nasopharyngeal cancer; Oesophageal cancer
  • Phase I Pancreatic cancer; Psoriasis

Most Recent Events

  • 14 Jul 2017 Betta Pharmaceuticals plans a phase II trial for Psoriasis (In adults, In the elderly) (Topical) (NCT03222622)
  • 08 Jun 2017 Betta Pharmaceuticals completes a phase I trial in Psoriasis in China (Topical) (NCT02801435)
  • 19 Feb 2017 Betta Pharmaceuticals completes a phase I trial in Psoriasis in New Zealand (Topical) (NCT02574091)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top